Affiliation: Erasmus MC
Country: The Netherlands
- Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Brenda C M de Winter
Erasmus Medical Center, Department of Hospital Pharmacy, Clinical Pharmacology Unit, Rotterdam, The Netherlands
Expert Opin Drug Metab Toxicol 3:251-61. 2007..Preliminary outcomes of these studies showed conflicting results and longer follow up is needed to further clarify the role of therapeutic drug monitoring in increasing the therapeutic potential of MMF...
- Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipientsBrenda C M de Winter
Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands
Clin Pharmacokinet 47:827-38. 2008..The pharmacokinetics of mycophenolic acid (MPA) were compared in renal transplant patients receiving either mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS)...
- Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune diseaseBrenda C M de Winter
Department of Hospital Pharmacy, Erasmus University Medical Center, Room L 056, PO Box 2040, Rotterdam 3000 CA, The Netherlands
Ther Drug Monit 31:382-90. 2009..The predictive performance was good and comparable to those of the multiple linear regression method. Due to its flexibility with respect to sample times, the MAP-BE may be preferred over the multiple linear regression method...
- Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune diseaseBrenda C M de Winter
Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus University Medical Center, Rotterdam, The Netherlands
Ther Drug Monit 32:606-14. 2010..6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively. In conclusion, plasma albumin concentrations and cyclosporine predose concentrations are able to describe the difference in MPA clearance among RTx, HSCTx, and AID patients...